Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Study on the Molecular Genetic Characteristics of Multiple Myeloma Patients in China

Yang Yang, Jingsong He, Gaofeng Zheng, Xiaoyan Han, Yang Nie, Li Sun, Haoran Ma, Ying Wu, Jie Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6816.

https://doi.org/10.1182/blood-2024-202862

Published: 2024

Journal Articles

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Chenyun Wang, Jinuo Wang, Yang Yang, Donghua He, Gaofeng Zheng, Xiaoyan Han, Jingsong He, Jinping Ying, Wenjun Wu, Zhen Cai

Blood (2024) 144 (Supplement 1): 6913.

https://doi.org/10.1182/blood-2024-201472

Published: 2024

Journal Articles

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Qingxiao Chen, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Jing Chen, Xiaoyan Han, Li Yang, Wenjun Wu, YI LI, Donghua He, Jingsong He, Zhen Cai

Blood (2024) 144 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2024-197887

Published: 2024

Journal Articles

Anomalous Peaks Observed in the Mass Spectrometry of Light Chains Correlate with the Diagnosis of AL Amyloidosis

Mengmeng Dong, Xiao Xiao, Zhen Cai, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Li Yang, Haimeng Yan

Blood (2024) 144 (Supplement 1): 6894.

https://doi.org/10.1182/blood-2024-210534

Published: 2024

Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li

Blood (2023) 142 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2023-184373

Published: 2023

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, Gaofeng Zheng, Xiaoyan Han, Donghua He, Tao Cheng, Zhen Cai

Blood (2023) 142 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2023-187906

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Donghua He, Xinyi Meng, Jingsong He, Wenjun Wu, Jinuo Wang, Chunting Zhu, Xiaoyan Han, Yi Zhao, Gaofeng Zheng, Yi Li, Xing Guo, Qingxiao Chen, Fangshu Guan, Zhen Cai

Blood (2023) 142 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2023-184689

Published: 2023

Journal Articles

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Shuchan Li, Xiaoyan Han, Gaofeng Zheng, Jingsong He, Wenjun Wu, Yang Yang, Qingxiao Chen, Donghua He, Mengmeng Dong, Jinuo Wang, Yi Li, Li Yang, Zhen Cai

Blood (2023) 142 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2023-184617

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Wenjun Wu, Yi Zhao, Yi Li, Zhen Cai

Blood (2023) 142 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2023-184794

Published: 2023

Journal Articles

Phase I Clinical Study of Humanized BCMA-Single-Domain Antibodies-Targeting CAR T (BCMA-CART) in Patients with Relapsed/Refractory Multiple Myeloma

Gaofeng Zheng, Heng Mei, Gang Ye, Ling Zhou, Cheng Wen, Zhuoxiao Cao, Zhen Cai

Blood (2023) 142 (Supplement 1): 3489.

https://doi.org/10.1182/blood-2023-186619

Published: 2023

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, GaoFeng Zheng, Xiaoyan Han, Donghua He, He Huang, Zhen Cai

Blood (2022) 140 (Supplement 1): 12102–12103.

https://doi.org/10.1182/blood-2022-168017

Published: 2022

Journal Articles

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Donghua He, Chunting Zhu, Xing Guo, Xin Huang, Xiaoyan Han, GaoFeng Zheng, Yi Zhao, Yang Yang, Wenjun Wu, Jimei Ge, Enfan Zhang, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 12813–12814.

https://doi.org/10.1182/blood-2022-166394

Published: 2022

Journal Articles

High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients

Mengmeng Dong, Jinna Zhang, Qingxiao Chen, Honghua He, Haimeng Yan, Gaofeng Zheng, Xiaoyan Han, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2022-156536

Published: 2022

Journal Articles

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

XiaoYan Yue, GaoFeng Zheng, Donghua He, Yang Yang, Xiaoyan Han, Yi LI, Yi Zhao, Qingxiao Chen, WenJun Wu, He Huang, Zhen Cai, Jingsong He

Blood (2022) 140 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2022-159859

Published: 2022

Journal Articles

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Zhen Cai, Zonghai Li, Huijuan Wang, Lingzhi Yan, Yin Wu, Xiaolan Shi, Wen Gao, Shuang Yan, Wei Wang, Xiaoyan Han, Gaofeng Zheng, Yanling Wen, Jun Xiao, Huamao Wang, Xiaole Tang

Blood (2021) 138 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2021-150124

Published: 2021

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD PhD, Chengcheng Fu, MD PhD, Zhen Cai, MD PhD, Zonghai Li, MD PhD, Huijuan Wang, MD PhD, Lingzhi Yan, MD PhD, Yin Wu, MD PhD, Xiaolan Shi, MD PhD, Wen Gao, MD, Shuang Yan, MD, Wei Wang, MDPhD, Xiaoyan Han, MD PhD, Gaofeng Zheng, MD PhD, Yanling Wen, MD, Jun Xiao, MD, Huamao Wang, PhD, Hong Ma, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-140727

Published: 2020

Journal Articles

Iron Metabolism before Allo-HSCT in Patients with Acute Leukemia and Impact of Iron Overload on Transplantation

Jimin Shi, Xuying Pei, Yi Luo, Yamin Tan, Yanmin Zhao, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Gaofeng Zheng, Jie Zhang, Maofang Lin, Zhen Cai, He Huang, MD PhD

Blood (2016) 128 (22): 2461.

https://doi.org/10.1182/blood.V128.22.2461.2461

Published: 2016

Journal Articles

Efficacy and Safety of Bortezomib Based Regimens Retreatment in Relapsed Multiple Myeloma Patients: Results from a Retrospective Study.

Wenjun Wu, MD, Gaofeng Zheng, MD, Xiaoyan Han, MD, Yi Zhao, PhD, Donghua He, PhD, Yang Yang, PhD, Jingsong He, PhD, Weiyan Zheng, Jie Sun, MD PhD, Jimin Shi, Guoqing Wei, MD PhD, He Huang, MD PhD, Zhen Cai

Blood (2015) 126 (23): 5387.

https://doi.org/10.1182/blood.V126.23.5387.5387

Published: 2015

NARROW

Study on the Molecular Genetic Characteristics of Multiple Myeloma Patients in China

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Anomalous Peaks Observed in the Mass Spectrometry of Light Chains Correlate with the Diagnosis of AL Amyloidosis

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Phase I Clinical Study of Humanized BCMA-Single-Domain Antibodies-Targeting CAR T (BCMA-CART) in Patients with Relapsed/Refractory Multiple Myeloma

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Iron Metabolism before Allo-HSCT in Patients with Acute Leukemia and Impact of Iron Overload on Transplantation

Efficacy and Safety of Bortezomib Based Regimens Retreatment in Relapsed Multiple Myeloma Patients: Results from a Retrospective Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only